How to buy Moleculin Biotech stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Moleculin Biotech stock

Own Moleculin Biotech stock in just a few minutes.

Moleculin Biotech, Inc is a biotechnology business based in the US. Moleculin Biotech shares (MBRX) are listed on the NASDAQ and all prices are listed in US Dollars. Moleculin Biotech employs 10 staff and has a market cap (total outstanding shares value) of USD$105 million.

How to buy shares in Moleculin Biotech

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Moleculin Biotech. Find the stock by name or ticker symbol: MBRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Moleculin Biotech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Moleculin Biotech, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Moleculin Biotech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Moleculin Biotech share price

Use our graph to track the performance of MBRX stocks over time.

Moleculin Biotech shares at a glance

Information last updated 2021-04-16.
52-week rangeUSD$3.1601 - USD$9.3
50-day moving average USD$4.0188
200-day moving average USD$4.7423
Wall St. target priceUSD$20.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.32

Buy Moleculin Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Moleculin Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Moleculin Biotech financials

Gross profit TTM USD$0
Return on assets TTM -45.47%
Return on equity TTM -104.14%
Profit margin 0%
Book value $1.539
Market capitalisation USD$105 million

TTM: trailing 12 months

Shorting Moleculin Biotech shares

There are currently 514,187 Moleculin Biotech shares held short by investors – that's known as Moleculin Biotech's "short interest". This figure is 71% up from 300,746 last month.

There are a few different ways that this level of interest in shorting Moleculin Biotech shares can be evaluated.

Moleculin Biotech's "short interest ratio" (SIR)

Moleculin Biotech's "short interest ratio" (SIR) is the quantity of Moleculin Biotech shares currently shorted divided by the average quantity of Moleculin Biotech shares traded daily (recently around 2.1 million). Moleculin Biotech's SIR currently stands at 0.24. In other words for every 100,000 Moleculin Biotech shares traded daily on the market, roughly 240 shares are currently held short.

However Moleculin Biotech's short interest can also be evaluated against the total number of Moleculin Biotech shares, or, against the total number of tradable Moleculin Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moleculin Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Moleculin Biotech shares in existence, roughly 20 shares are currently held short) or 0.0184% of the tradable shares (for every 100,000 tradable Moleculin Biotech shares, roughly 18 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moleculin Biotech.

Find out more about how you can short Moleculin Biotech stock.

Moleculin Biotech share dividends

We're not expecting Moleculin Biotech to pay a dividend over the next 12 months.

Have Moleculin Biotech's shares ever split?

Moleculin Biotech's shares were split on a 1:6 basis on 31 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Moleculin Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Moleculin Biotech shares which in turn could have impacted Moleculin Biotech's share price.

Moleculin Biotech share price volatility

Over the last 12 months, Moleculin Biotech's shares have ranged in value from as little as $3.1601 up to $9.3. A popular way to gauge a stock's volatility is its "beta".

MBRX.US volatility(beta: 2.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moleculin Biotech's is 2.0514. This would suggest that Moleculin Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Moleculin Biotech overview

Moleculin Biotech, Inc. , a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site